Aspargo Labs, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
Aspargo Labs, a specialty pharmaceutical and med-tech company, has filed an amendment to its Form S-1 registration statement for a direct listing on the NYSE, aiming to improve patient outcomes through innovative drug delivery systems.
Aspargo Labs, a specialty pharmaceutical and med-tech company, has filed an S-1 registration statement for a direct listing of its common stock on the NYSE, aiming to raise capital for commercializing its Sildenafil Oral Suspension and developing innovative drug delivery devices.